Amphastar Pharmaceuticals, Inc. Overview
Pro stress-test →Amphastar Pharmaceuticals develops and manufactures technically challenging injectable and inhalation medications, including both generic and proprietary pharmaceutical products. The company is undergoing a significant strategic pivot from legacy generic products toward a diversified portfolio of proprietary and biosimilar products, while facing near-term pressure from declining legacy generics and margin compression.
Strategic Profile
Pro stress-test →The company projects that proprietary and biosimilar products will represent 85% of its pipeline by 2026, reflecting management's conviction that the company's future lies in complex, differentiated therapies rather than commodity generics. Amphastar's vertically integrated manufacturing capabilities and technical expertise in peptides, inhalation products, and biosimilars provide a competitive advantage, offering quality control advantages and potentially faster development timelines.
Competitive Landscape
Pro stress-test →Amphastar competes in the injectable and inhalation pharmaceuticals space against larger competitors including Eli Lilly, Bristol-Myers Squibb, and various generic manufacturers. The company differentiates through technical expertise in complex formulations and vertical integration. Competitive pressures from generic glucagon, epinephrine, and phytonadione are expected to offset new product growth.
Industry Context
Amphastar Pharmaceuticals, Inc. operates in Specialty Pharmaceuticals / Complex Generics and Proprietary Injectables.
Key facts
Founded: 2004 · Headquarters: Rancho Cucamonga, California · Revenue: $719.9 million (FY2025)